IP Library Granted Patent US 8,999,297
Granted Patent B2
US 8,999,297 · App. 12/460,044 · Granted Apr 7, 2015

Hemostatic agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,297
App. No.
12/460,044
Granted
Apr 7, 2015
Kind
B2
Abstract

A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.

Claims (43)

1. An aqueous dental hemostatic agent comprising:

at least one water-soluble magnesium salt selected from the group consisting of magnesium chloride, magnesium sulfate, magnesium acetate, magnesium citrate and combinations thereof, said at least one magnesium salt at between 40-60 weight percent of the agent;

an acidic compound;

a pH balancing compound between 2-15 weight percent of the agent;

and

KELTROL® T-630 xanthan gum at between 0.5-10.0 weight percent of the agent,

said agent having a pH value between about 3.0-8.0.

2. The hemostatic agent according to claim 1 wherein said at least one water-soluble magnesium salt comprises a first water-soluble magnesium salt and a second water-soluble magnesium salt, and wherein said first water-soluble magnesium salt comprises magnesium chloride.

3. The hemostatic agent according to claim 2 wherein said second water-soluble magnesium salt comprises magnesium sulfate or magnesium acetate.

4. The hemostatic agent according to claim 2 , wherein said first water-soluble magnesium salt comprises between about 1.0-50.0 weight percent of the hemostatic agent.

5. The hemostatic agent according to claim 3 wherein said second water-soluble magnesium salt comprises between about 0.5-40.0 weight percent of the hemostatic agent.

6. An aqueous, clear dental hemostatic agent comprising:

a first water-soluble magnesium compound comprising between 1.0-50.0 weight percent of the agent, and a second water-soluble magnesium compound comprising between 0.5-40.0 weight percent of the agent, the first and second water-soluble magnesium compounds selected from the group consisting of magnesium chloride, magnesium sulfate, magnesium acetate, and magnesium citrate, the combination of said first and second water-soluble magnesium compounds comprising between 40.0-60.0 weight percent of the agent;

a first acidic compound; and

a xanthan gum comprising between 0.5-10.0 weight percent,

said agent having a pH value between about 3.0-8.0;

wherein said dental hemostatic agent is a uniform composition with no suspended solids.

7. The agent according to claim 6 further comprising a polyol.

8. The agent according to claim 6 further comprising a second acidic compound.

9. The agent according to claim 1 , wherein said acidic compound is a dicarboxylic acid compound.

10. The agent according to claim 9 , wherein said dicarboxylic acid compound is selected from malonic acid and oxalic acid.

11. The agent according to claim 1 , wherein the pH balancing compound comprises triethanolamine at between 2.0-20 weight percent of the hemostatic agent.

12. The agent according to claim 6 , wherein said first acidic compound is a dicarboxylic acid compound.

13. The agent according to claim 12 , wherein said dicarboxylic acid compound is selected from malonic acid and oxalic acid.

14. The agent according to claim 6 , further comprising triethanolamine at between 2.0-20 weight percent of the hemostatic agent.

15. The agent according to claim 6 , wherein said first water-soluble magnesium compound is magnesium chloride and wherein said second water-soluble magnesium compound is magnesium sulfate.

16. A hemostatic agent obtained in a process comprising the steps of:

(a) dissolving at least one magnesium salt in a volume of water;

(b) combining at least one acidic compound with the mixture of step (a);

(c) adding a pH balancing compound to the mixture of step (b) and agitating to provide a clear solution;

(d) adding a polyol to the clear solution of step (c);

(e) adding KELTROL® T-630 xanthan gum to the mixture of step (d);

(f) agitating the mixture of step (e) to completely hydrate the xanthan gum, thereby forming a uniform clear gel with no suspended solids and a pH between about 3.0 and about 8.0, the uniform gel comprising:

about 40 weight percent to about 60 weight percent of the at least one magnesium salt;

about 0.1 weight percent to about 20 weight percent of the at least one acidic compound;

about 1 weight percent to about 20 weight percent of a sweetener;

up to about 20 weight percent of the pH balancing compound;

about 5 weight percent to about 25 weight percent of the polyol; and

about 0.5 weight percent to about 10.0 weight percent of the xanthan gum.

17. The hemostatic agent of claim 16 , wherein a first water-soluble magnesium salt is magnesium chloride and wherein a second water-soluble magnesium salt is magnesium sulfate.

18. The hemostatic agent of claim 16 , wherein said acidic compound is a dicarboxylic acid compound selected from malonic acid and oxalic acid.

19. The hemostatic agent of claim 16 , wherein the pH balancing compound is triethanolamine.

20. The hemostatic agent of claim 16 , wherein the said polyol is polyethylene oxide 400.

Assignments (10)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED ON REEL 67010 FRAME 306. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Apr 8, 2024
From: MARANON CAPITAL, L.P., AS AGENT
To: INTER-MED, INC.; APEX DENTAL MATERIALS, LLC
Reel/Frame 067029/0280 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE TO RELEASE OF SECURITY INTEREST PREVIOUSLY RECORDED ON REEL 67010 FRAME 306. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Apr 8, 2024
From: MARANON CAPITAL, L.P., AS AGENT
To: INTER-MED, INC.; APEX DENTAL MATERIALS, LLC
Reel/Frame 067028/0628 →
SECURITY INTEREST Recorded Apr 4, 2024
From: MARANON CAPITAL, L.P., AS AGENT
To: INTER-MED, INC.; APEX DENTAL MATERIALS, LLC
Reel/Frame 067010/0306 →
SECURITY INTEREST Recorded Apr 3, 2024
From: INTER-MED, INC.
To: BMO BANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 066993/0755 →
RELEASE OF SECURITY INTEREST Recorded Apr 11, 2022
From: AVANTE MEZZANINE PARTNERS SBIC II, L.P.
To: INTER-MED, INC.
Reel/Frame 059558/0004 →
SECURITY INTEREST Recorded Apr 7, 2022
From: INTER-MED, INC.; APEX DENTAL MATERIALS, LLC
To: MARANON CAPITAL, L.P., AS ADMINISTRATIVE AGENT
Reel/Frame 059530/0599 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2018
From: WISCONSIN BANK & TRUST
To: INTER-MED, INC.
Reel/Frame 046505/0861 →
SECURITY INTEREST Recorded Jul 2, 2018
From: INTER-MED, INC.
To: AVANTE MEZZANINE PARTNERS SBIC II, L.P.
Reel/Frame 046253/0147 →
SECURITY INTEREST Recorded Nov 6, 2015
From: INTER-MED, INC.; POND, GARY J.
To: WISCONSIN BANK & TRUST
Reel/Frame 036975/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2015
From: POND, GARY J.; BAETEN, JOHN
To: INTER-MED, INC.
Reel/Frame 034935/0441 →